Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators

US7723333B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Anders Broo · Timrå, SE
• Robert Judkins · Mölndal, SE
• Lanna Li · Timrå, SE
• Eva-Lotte Lindstedt-Alstermark · Mölndal, SE
• Pernilla Sandberg · Timrå, SE
• Marianne Swanson · Gothenburg, SE
• Lars Weidolf · Timrå, SE
• Kay Brickmann · Timrå, SE
• Patrik Holm · Vaasa, FI

Key dates

• Filing date: Jan 9, 2006
• Grant date: May 25, 2010
• Expiry date: Jan 9, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to certain novel compounds of the formula (I)to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.